Home

Tuesday, May 23, 2017 - 14:37
Physicians can support their hair loss patients by sharing information on the different products now available to camouflage thinning hair, according to a recent study published in the June 2017 issue of the Journal of the American Academy of Dermatology. For “Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients,” researchers Christina M. Ring, et al, of Thomas Jefferson University in Philadelphia, posted a 12-question survey on various online hair loss forums and blog sites.
http://medestheticsmag.com/hair-loss-camouflage-products-improve-self-esteem
Tuesday, May 23, 2017 - 14:37
Physicians can support their hair loss patients by sharing information on the different products now available to camouflage thinning hair, according to a recent study published in the June 2017 issue of the Journal of the American Academy of Dermatology. For “Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients,” researchers Christina M. Ring, et al, of Thomas Jefferson University in Philadelphia, posted a 12-question survey on various online hair loss forums and blog sites.
http://medestheticsmag.com/hair-loss-camouflage-products-improve-self-esteem
Tuesday, May 23, 2017 - 14:33
On May 18, 2017, the California State Senate approved SB 790 (Health care providers: gifts and benefits), a bill that prohibits manufacturers of prescribed products from offering or providing gifts to healthcare providers. The bill defines a gift as “anything of value provided for free to a healthcare provider, or a payment, food, entertainment, travel, subscription, advance, service, or anything else of value provided to a healthcare provider, unless it is a specified allowable expenditure or the healthcare provider reimburses the cost at fair market value.”
http://medestheticsmag.com/california-advances-bill-limit-drugmaker-payments-physicians

Advertisement - Box 1

Advertisement - Box 2

Tuesday, May 23, 2017 - 14:33
On May 18, 2017, the California State Senate approved SB 790 (Health care providers: gifts and benefits), a bill that prohibits manufacturers of prescribed products from offering or providing gifts to healthcare providers. The bill defines a gift as “anything of value provided for free to a healthcare provider, or a payment, food, entertainment, travel, subscription, advance, service, or anything else of value provided to a healthcare provider, unless it is a specified allowable expenditure or the healthcare provider reimburses the cost at fair market value.”
http://medestheticsmag.com/california-advances-bill-limit-drugmaker-payments-physicians
Monday, May 22, 2017 - 15:46
Q&A with Cosmoprof marketing director and mastermind Daniela Ciocan Cosmoprof North America (NA), the beauty industry’s biggest trade show, is nearly here! Beauty Store Business caught up with the show’s talented marketing director, Daniela Ciocan, to provide you with more information about this key business event that will take place July 9–12 in Las Vegas, Nevada.
http://beautystorebusiness.com/get-ready-cosmoprof-north-america-2017
Monday, May 22, 2017 - 14:07
Compassion, trust and a thirst for knowledge are the guiding principles at Vanek Plastic Surgery.By Laura BelizPLASTIC SURGEON Paul Vanek, MD, FACS, was drawn to the field of medicine at a young age. When he was 8 years old his father suffered a traumatic brain injury, which gave Dr. Vanek a unique perspective on the care that physicians provide. “The doctors who took care of my father and comforted my mother really had that ability to make people feel better, even though it was a very out of control situation,” he recalls. “It was that experience that led me into medicine.”
http://medestheticsmag.com/faith-science

Advertisement - Box 3

Advertisement - Box 4

Thursday, May 11, 2017 - 15:04
The U.S. Food & Drug Administration has accepted Aclaris Therapeutics’ New Drug Application (NDA) for A-101 40% topical solution, a high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). The NDA indicates that the company’s application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical medication for the treatment of SK.
http://medestheticsmag.com/fda-accepts-nda-first-noninvasive-topical-sk-treatment
Thursday, May 11, 2017 - 15:04
The U.S. Food & Drug Administration has accepted Aclaris Therapeutics’ New Drug Application (NDA) for A-101 40% topical solution, a high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). The NDA indicates that the company’s application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical medication for the treatment of SK.
http://medestheticsmag.com/fda-accepts-nda-first-noninvasive-topical-sk-treatment
Thursday, May 11, 2017 - 15:01
In an effort to identify the most and least effective treatment options for striae distensae (SD), Nicholas A. Ross, MD, et al, conducted a literature review of PubMed, MEDLINE, Scopus, Embase and Google scholar, reviewing published studies from 1773 to August 6, 2016. They identified 68 articles that met their inclusion and exclusion criteria, noting that there were few randomized, controlled trials that evaluated long-term efficacy.
http://medestheticsmag.com/fractionated-lasers-are-best-option-striae-distensae

Pages

Advertisement - Box 5

Advertisement - Box 6